{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:24:55Z","timestamp":1787063095084,"version":"build-2736575974"},"reference-count":33,"publisher":"Elsevier BV","issue":"13","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T00:00:00Z","timestamp":1718150400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018573","name":"Sun Yat-sen University Cancer Center","doi-asserted-by":"publisher","award":["TTP - SYSUCC -202406"],"award-info":[{"award-number":["TTP - SYSUCC -202406"]}],"id":[{"id":"10.13039\/501100018573","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["82173278"],"award-info":[{"award-number":["82173278"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2017A030313617"],"award-info":[{"award-number":["2017A030313617"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2022A1515010290"],"award-info":[{"award-number":["2022A1515010290"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81773103"],"award-info":[{"award-number":["81773103"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.heliyon.2024.e33001","type":"journal-article","created":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T03:33:41Z","timestamp":1718854421000},"page":"e33001","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Cytidine triphosphate synthase 1-mediated metabolic reprogramming promotes proliferation and drug resistance in multiple myeloma"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8635-4867","authenticated-orcid":false,"given":"Hanying","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanzhou","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinnan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanxin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2024.e33001_bib1","first-page":"7","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"Ca - Cancer J. Clin."},{"key":"10.1016\/j.heliyon.2024.e33001_bib2","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","article-title":"Global burden of multiple myeloma: a systematic analysis for the Global Burden of Disease Study 2016","volume":"4","author":"Cowan","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.heliyon.2024.e33001_bib3","first-page":"3071","article-title":"The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells","volume":"61","author":"Hideshima","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e33001_bib4","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1182\/blood-2007-01-065888","article-title":"Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma","volume":"110","author":"Kuhn","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e33001_bib5","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1182\/blood-2014-06-581611","article-title":"Oral therapy for multiple myeloma: ixazomib arriving soon","volume":"124","author":"Moreau","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e33001_bib6","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/sj.thj.6200031","article-title":"Thalidomide in patients with advanced multiple myeloma","volume":"1","author":"Yakoub-Agha","year":"2000","journal-title":"Hematol. J."},{"key":"10.1016\/j.heliyon.2024.e33001_bib7","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1182\/blood-2002-03-0996","article-title":"Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma","volume":"100","author":"Richardson","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e33001_bib8","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1200\/JCO.2004.10.052","article-title":"Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma","volume":"22","author":"Schey","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2024.e33001_bib9","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1200\/JCO.2013.54.8164","volume":"32","author":"Roussel","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2024.e33001_bib10","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e33001_bib11","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12916-022-02305-4","article-title":"Selinexor plus low-dose dexamethasone in Chinese patients with relapsed\/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study","volume":"20","author":"Qiu","year":"2022","journal-title":"BMC Med."},{"key":"10.1016\/j.heliyon.2024.e33001_bib12","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41591-022-02182-7","article-title":"Allogeneic BCMA-targeting CAR T cells in relapsed\/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results","volume":"29","author":"Mailankody","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.heliyon.2024.e33001_bib13","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.heliyon.2024.e33001_bib14","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-020-00359-2","article-title":"Multiple myeloma current treatment algorithms","volume":"10","author":"Rajkumar","year":"2020","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.heliyon.2024.e33001_bib15","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1038\/s41375-021-01206-4","article-title":"A prognostic survival model based on metabolism-related gene expression in plasma cell myeloma","volume":"35","author":"Huang","year":"2021","journal-title":"Leukemia"},{"issue":"40","key":"10.1016\/j.heliyon.2024.e33001_bib16","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2107968118","article-title":"Structural basis for isoform-specific inhibition of human CTPS1","volume":"118","author":"Lynch","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e33001_bib17","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.202302066","article-title":"Differential roles of CTP synthetases CTPS1 and CTPS2 in cell proliferation","volume":"6","author":"Minet","year":"2023","journal-title":"Life Sci. Alliance"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e33001_bib18","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41375-023-02071-z","article-title":"CTPS1 is a novel therapeutic target in multiple myeloma which synergizes with inhibition of CHEK1, ATR or WEE1","volume":"38","author":"Pfeiffer","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.heliyon.2024.e33001_bib19","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.plipres.2008.03.004","article-title":"CTP synthetase and its role in phospholipid synthesis in the yeast Saccharomyces cerevisiae","volume":"47","author":"Chang","year":"2008","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.heliyon.2024.e33001_bib20","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"van de Donk","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.heliyon.2024.e33001_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.973836","article-title":"Drug resistance in multiple myeloma: soldiers and weapons in the bone marrow niche","volume":"12","author":"Solimando","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.heliyon.2024.e33001_bib22","first-page":"171","article-title":"Drug resistance and minimal residual disease in multiple myeloma","volume":"5","author":"Gozzetti","year":"2022","journal-title":"Cancer Drug Resist"},{"key":"10.1016\/j.heliyon.2024.e33001_bib23","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/nature13386","article-title":"CTP synthase 1 deficiency in humans reveals its central role in lymphocyte proliferation","volume":"510","author":"Martin","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2024.e33001_bib24","doi-asserted-by":"crossref","first-page":"83187","DOI":"10.18632\/oncotarget.13077","article-title":"Identification and validation of differentially expressed proteins in epithelial ovarian cancers using quantitative proteomics","volume":"7","author":"Qu","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.heliyon.2024.e33001_bib25","first-page":"671","article-title":"POLR1B is upregulated and promotes cell proliferation in non-small cell lung cancer","volume":"19","author":"Yang","year":"2020","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.heliyon.2024.e33001_bib26","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12967-021-03206-5","article-title":"CTPS1 promotes malignant progression of triple-negative breast cancer with transcriptional activation by YBX1","volume":"20","author":"Lin","year":"2022","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.heliyon.2024.e33001_bib27","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1158\/0008-5472.CAN-21-1707","article-title":"Combined inactivation of CTPS1 and ATR is synthetically lethal to MYC-overexpressing cancer cells","volume":"82","author":"Sun","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e33001_bib28","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/bjh.18878","article-title":"MYC-induced cytidine metabolism regulates survival and drug resistance via cGas-STING pathway in mantle cell lymphoma","volume":"202","author":"Liang","year":"2023","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e33001_bib29","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000864","article-title":"CTP synthase 1 is a novel therapeutic target in lymphoma","volume":"7","author":"Asnagli","year":"2023","journal-title":"Hemasphere"},{"key":"10.1016\/j.heliyon.2024.e33001_bib30","article-title":"TSC22D3 as an immune-related prognostic biomarker for acute myeloid leukemia","volume":"26","author":"Li","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.heliyon.2024.e33001_bib31","article-title":"A new autophagy-related nomogram and mechanism in multiple myeloma","author":"Huang","year":"2023","journal-title":"Genes & Diseases"},{"key":"10.1016\/j.heliyon.2024.e33001_bib32","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1186\/1471-2105-9-559","article-title":"WGCNA: an R package for weighted correlation network analysis","volume":"9","author":"Langfelder","year":"2008","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.heliyon.2024.e33001_bib33","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nat. Methods"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024090327?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024090327?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T22:43:18Z","timestamp":1778884998000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024090327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":33,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S2405844024090327"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e33001","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytidine triphosphate synthase 1-mediated metabolic reprogramming promotes proliferation and drug resistance in multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e33001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e33001"}}